<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973333</url>
  </required_header>
  <id_info>
    <org_study_id>IMC-C103C-101</org_study_id>
    <nct_id>NCT03973333</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab</brief_title>
  <official_title>A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunocore Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunocore Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC Â®)&#xD;
      designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This&#xD;
      is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult&#xD;
      patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for&#xD;
      MAGE-A4.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IMC-C103C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable&#xD;
      tumors which include select Advanced Solid Tumors and will be conducted in two phases.&#xD;
&#xD;
        1. To identify the MTD and/or expansion dose of IMC-C103C as a single agent administered IV&#xD;
           and SC Q1W and administered Q1W in combination with Q3W atezolizumab.&#xD;
&#xD;
        2. To assess the preliminary anti-tumor activity of IMC-C103C in one or more selected&#xD;
           indications, as a single agent administered Q1W.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2019</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential from arm monotherapy IV dose escalation is opened first; then monotherapy SC dose escalation, monotherapy expansion and combination dose escalation may run</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Incidence of dose-limiting toxicities (DLT)</measure>
    <time_frame>From first dose to DLT period (28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: incidence and severity of adverse events (AE)</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in laboratory parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in vital signs</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in electrocardiogram parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>QTcF interval absolute values and changes from baseline will be summarized</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: dose interruptions, reductions, and discontinuations</measure>
    <time_frame>from first dose through last dose (anticipated for up to 12-24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Best overall response (BOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2: incidence and severity of adverse events (AE)</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: changes in laboratory parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: changes in vital signs</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: changes in electrocardiogram parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>QTcF interval absolute values and changes from baseline will be summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: dose interruptions, reductions, and discontinuations</measure>
    <time_frame>from first dose through last dose (anticipated for up to 12-24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Best overall response</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>from first dose to within approx, 2 weeks of last dose/4 weeks (IMC-C103C AUC will be assessed weekly for 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The maximum observed plasma drug concentration after single dose administration (Cmax)</measure>
    <time_frame>from first dose to within approx, 2 weeks of last dose/4 weeks (IMC-C103C AUC will be assessed weekly for 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>from first dose to within approx, 2 weeks of last dose/4 weeks (IMC-C103C AUC will be assessed weekly for 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The elimination half-life (t1/2)</measure>
    <time_frame>from first dose to within approx, 2 weeks of last dose/4 weeks (IMC-C103C AUC will be assessed weekly for 4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity the incidence of anti-drug antibody formation</measure>
    <time_frame>from first dose to 14 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lymphocyte counts over time</measure>
    <time_frame>from first dose to approx 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum cytokines over time</measure>
    <time_frame>from first dose to approx.. 4wks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Select Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>IMC-C103C - Monotherapy IV dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n= approximately 28 patients to establish the MTD/expansion dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-C103C and atezolizumab dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=approximately 12 patients to establish the MTD/expansion dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-C103C - expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be enrolled n=9-24 per expansion cohort (up to 4 total): metastatic/unresectable tumors of interest patients treated at the expansion dose of IMC-C103C to assess preliminary anti-tumor efficacy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-C103C monotherapy SC dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be enrolled n=9-12 to establish the MTD/expansion dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMC-C103C</intervention_name>
    <description>Weekly IV infusions</description>
    <arm_group_label>IMC-C103C - Monotherapy IV dose escalation</arm_group_label>
    <arm_group_label>IMC-C103C - expansion</arm_group_label>
    <arm_group_label>IMC-C103C and atezolizumab dose escalation</arm_group_label>
    <arm_group_label>IMC-C103C monotherapy SC dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMC-C103C</intervention_name>
    <description>Weekly infusions</description>
    <arm_group_label>IMC-C103C and atezolizumab dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMC-C103C</intervention_name>
    <description>Weekly IV infusions</description>
    <arm_group_label>IMC-C103C and atezolizumab dose escalation</arm_group_label>
    <arm_group_label>IMC-C103C monotherapy SC dose escalation</arm_group_label>
    <other_name>Atezolizumab</other_name>
    <other_name>Q3W</other_name>
    <other_name>TECENTRIQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HLA-A*02:01 positive&#xD;
&#xD;
          2. MAGE-A4 positive tumor&#xD;
&#xD;
          3. ECOG PS 0 or 1&#xD;
&#xD;
          4. Selected advanced solid tumors&#xD;
&#xD;
          5. Relapsed from, refractory to, or intolerant of standard therapy&#xD;
&#xD;
          6. Measurable disease per RECIST v1.1 (expansion)&#xD;
&#xD;
          7. If applicable, must agree to use highly effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptomatic or untreated central nervous system metastasis&#xD;
&#xD;
          2. Inadequate washout from prior anticancer therapy&#xD;
&#xD;
          3. Significant ongoing toxicity from prior anticancer treatment&#xD;
&#xD;
          4. Impaired baseline organ function as evaluated by out-of-range laboratory values&#xD;
&#xD;
          5. Clinically significant cardiac disease&#xD;
&#xD;
          6. Active infection requiring systemic antibiotic therapy&#xD;
&#xD;
          7. Known history of human immunodeficiency virus (HIV)&#xD;
&#xD;
          8. Active hepatitis B virus (HBV) or hepatitis C virus (HCV)&#xD;
&#xD;
          9. Ongoing treatment with systemic steroids or other immunosuppressive therapies&#xD;
&#xD;
         10. Significant secondary malignancy&#xD;
&#xD;
         11. Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Dar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Immunocore Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed Dar, MD</last_name>
    <phone>4845345261</phone>
    <email>clinicaltrials@immunocore.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Mata, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rodolfo Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehenvise Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hui Amy Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Breelyn Wilky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medicine &amp; Biological Sciences</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randy F Sweis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Randy F Sweis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Segal</last_name>
    </contact>
    <investigator>
      <last_name>Neil Segal, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kathleen Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rita Axelrod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diwakar Davar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Johnson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Blumenschein, MD</last_name>
    </contact>
    <investigator>
      <last_name>George Blumenschein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Garralda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ignacio Melero Bermejo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz - PPDS</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaime Feliu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ignacio Melero Bermejo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeff Evans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Hospital Cancer Center</name>
      <address>
        <city>Bebington</city>
        <zip>CH634JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara King</last_name>
    </contact>
    <investigator>
      <last_name>Joseph Sacco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fosia Yusuf</last_name>
    </contact>
    <investigator>
      <last_name>Hendrik-Tobias Arkenau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fiona Thistlethwaite, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juanita Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ImmTAC, IMC-C103C, MAGE-A4, immunotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

